Novo Nordisk Says CagriSema Produced 25% Average Weight Loss in Women
Novo Nordisk said its experimental CagriSema showed average weight loss of 25% among women with obesity or overweight, based on analysis after completion of a late-stage study.
Novo Nordisk OMXCOP:NOVO_B said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss on average in women with obesity or overweight, according to data analyzed after the completion of a late-stage study.CagriSema, viewed as a successor to the Danish drugmaker's blockb…